Young Allan H, Newham James I
University of Newcastle, Newcastle upon Tyne, UK.
J Psychopharmacol. 2006 Mar;20(2 Suppl):17-22. doi: 10.1177/1359786806063072.
Lithium has been used for the medical treatment of bipolar disorder for over 50 years. The purpose of this paper is to review the evidence base supporting the use of lithium in the maintenance phase of treatment of bipolar disorder and the limitations which reduce the clinical effectiveness of this medication. A selective review of the relevant literature was carried out. It is concluded that lithium is efficacious in the maintenance phase treatment of bipolar disorder, with the available evidence supporting a beneficial effect which prevents recurrence of mania; it is less clear if lithium prevents depressive episodes in bipolar disorder. A number of lines of evidence support the notion that lithium reduces suicidal acts and completed suicide. Lithium has a significant side effect burden and a narrow therapeutic index. It is also associated with an increased liability for new episodes, both manic and depressive, consequent upon stoppage of treatment. These factors limit the clinical effectiveness of lithium.
锂用于双相情感障碍的医学治疗已有50多年。本文旨在回顾支持锂在双相情感障碍维持治疗阶段使用的证据基础以及降低该药物临床疗效的局限性。对相关文献进行了选择性综述。得出的结论是,锂在双相情感障碍的维持治疗阶段有效,现有证据支持其具有预防躁狂复发的有益作用;锂是否能预防双相情感障碍的抑郁发作尚不清楚。多项证据支持锂能减少自杀行为和自杀既遂的观点。锂有显著的副作用负担且治疗指数狭窄。它还与停药后新的躁狂和抑郁发作风险增加有关。这些因素限制了锂的临床疗效。